

Torsten Zuberbier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3097679/publications.pdf>

Version: 2024-02-01

416
papers

34,642
citations

4658

85
h-index

4645

170
g-index

470
all docs

470
docs citations

470
times ranked

17793
citing authors

#	ARTICLE	IF	CITATIONS
1	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	5.7	392
2	A European survey of management approaches in chronic urticaria in children: EAACI pediatric urticaria taskforce. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	2.6	5
3	Proposal of 0.5Âmg of protein/100Âg of processed food as threshold for voluntary declaration of food allergen traces in processed foodâ€”A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA ² LEN position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1736-1750.	5.7	21
4	Annular urticarial lesions. <i>Clinics in Dermatology</i> , 2022, 40, 480-504.	1.6	2
5	Development and validation of combined symptomâ€”medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
6	Experienceâ€”based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: Where is the guidance?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1626-1630.	5.7	9
7	Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients. <i>Allergo Journal International</i> , 2022, 31, 161-171.	2.0	9
8	Allergies and COVIDâ€”19 vaccines: An ENDA/EAACI Position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2292-2312.	5.7	55
9	Allergen immunotherapy in MASKâ€”air users in realâ€”life: Results of a Bayesian mixedâ€”effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
10	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€”air^{Â®} realâ€”world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
11	FcÎ±RIâ€”and MRGPRX2â€”evoked acute degranulation responses are fully additive in human skin mast cells. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1906-1909.	5.7	14
12	MRGPRX2-Mediated Degranulation of Human Skin Mast Cells Requires the Operation of GÎ±i, GÎ±q, Ca ⁺⁺ Channels, ERK1/2 and PI3Kâ€”Interconnection between Early and Late Signaling. <i>Cells</i> , 2022, 11, 953.	4.1	17
13	Available and affordable complementary treatments for COVIDâ€”19: From hypothesis to pilot studies and the need for implementation. <i>Clinical and Translational Allergy</i> , 2022, 12, e12127.	3.2	6
14	Prevalence and risk factors of chronic urticaria in China: A nationwide crossâ€”sectional study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2233-2236.	5.7	6
15	Risk factors for severe reactions in food allergy: Rapid evidence review with metaâ€”analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2634-2652.	5.7	50
16	Chemokine Expression-Based Endotype Clustering of Chronic Rhinosinusitis. <i>Journal of Personalized Medicine</i> , 2022, 12, 646.	2.5	12
17	Comparison of rhinitis treatments using <sc>MASK</sc>â€”airÂ® data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8
18	The <sc>SCF</sc>/<sc>KIT</sc> axis in human mast cells: Capicua acts as potent <sc>KIT</sc> repressor and <sc>ERK</sc> predominates <sc>PI3K</sc>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3337-3349.	5.7	8

#	ARTICLE	IF	CITATIONS
19	Presentation of airway and general symptoms in COVID-19 caused by dominant <sc>SARS-CoV-2</sc> variants: A follow-up on <sc>ARIA</sc> consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3440-3444.	5.7	3
20	Usage patterns of oral H1-antihistamines in 10 European countries: A study using MASK-air [®] and Google Trends real-world data. World Allergy Organization Journal, 2022, 15, 100660.	3.5	4
21	Elicitors and phenotypes of adult patients with proven IgE-mediated food allergy and non-immune-mediated food hypersensitivity to food additives. Clinical and Experimental Allergy, 2022, 52, 1302-1310.	2.9	6
22	Legends of allergy and immunology: Jean Julien Raoul Bousquet; a Chemist, a Pharmacist, a Biologist, a Physician and "above all" an innovative scientist. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 399-402.	5.7	1
23	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic "An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
24	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
25	ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
26	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	5.7	83
27	MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β^2 -Arrestin and Lack of Correlation with the Fc μ RI Pathway. Journal of Investigative Dermatology, 2021, 141, 1286-1296.e4.	0.7	39
28	The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 816-830.	5.7	58
29	Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases. World Allergy Organization Journal, 2021, 14, 100498.	3.5	27
30	Spices to Control COVID-19 Symptoms: Yes, but Not Only!. International Archives of Allergy and Immunology, 2021, 182, 489-495.	2.1	23
31	Thymic Stromal Lymphopoietin Promotes MRGPRX2-Triggered Degranulation of Skin Mast Cells in a STAT5-Dependent Manner with Further Support from JNK. Cells, 2021, 10, 102.	4.1	24
32	Biologics for atopic diseases: Indication, side effect management, and new developments. Allergologie Select, 2021, 5, 1-25.	3.1	13
33	Practical recommendations for the allergological risk assessment of the COVID-19 vaccination " a harmonized statement of allergy centers in Germany. Allergologie Select, 2021, 5, 72-76.	3.1	22
34	Update of the S2k guideline on the management of IgE-mediated food allergies. Allergologie Select, 2021, 5, 195-243.	3.1	42
35	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. International Archives of Allergy and Immunology, 2021, 182, 324-338.	2.1	33
36	First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients. World Allergy Organization Journal, 2021, 14, 100494.	3.5	14

#	ARTICLE	IF	CITATIONS
37	Targeted micronutrition via holo-BLC based on the farm effect in house dust mite allergic rhinoconjunctivitis patients – first evaluation in a standardized allergen exposure chamber. <i>Allergo Journal International</i> , 2021, 30, 141-149.	2.0	18
38	Cytokines Stimulated by IL-33 in Human Skin Mast Cells: Involvement of NF- κ B and p38 at Distinct Levels and Potent Co-Operation with Fc μ RI and MRGPRX2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3580.	4.1	33
39	Practical handling of allergic reactions to COVID-19 vaccines. <i>Allergo Journal International</i> , 2021, 30, 79-95.	2.0	25
40	Digital Health Europe (DHE) Twinning on severe asthma – kick-off meeting report. <i>Journal of Thoracic Disease</i> , 2021, 13, 3215-3225.	1.4	0
41	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	2.9	8
42	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA – EAACI – GA ² – LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
43	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1805-1812.	3.8	14
44	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
45	ARIA – EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI – ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1624-1628.	5.7	66
46	Face masks suitable for preventing COVID-19 and pollen allergy. A study in the exposure chamber. <i>Allergo Journal International</i> , 2021, 30, 176-182.	2.0	14
47	Effects of allergen immunotherapy in the MASK – air study: a proof – of – concept analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3212-3214.	5.7	14
48	Cytokine Stimulation via MRGPRX2 Occurs with Lower Potency than by Fc μ RI-aggregation but with Similar Dependence on the ERK1/2 Module in Human Skin Mast Cells. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.7	8
49	Inhaled corticosteroids in early COVID-19 – A tale of many facets. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3540-3542.	5.7	3
50	Role of IL-17 in atopy – A systematic review. <i>Clinical and Translational Allergy</i> , 2021, 11, e12047.	3.2	23
51	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
52	White paper on peanut allergy – part 1: Epidemiology, burden of disease, health economic aspects. <i>Allergo Journal International</i> , 2021, 30, 261-269.	2.0	8
53	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK – air [®] . <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	3.2	31
54	Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3810-3813.	5.7	8

#	ARTICLE	IF	CITATIONS
55	Urtikaria. , 2021, , 741-747.		0
56	Guideline on management of suspected adverse reactions to ingested histamine - Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergology and Environmental Medicine (GPA), the Medical Association. Allergologie Select, 2021, 5, 305-314.	3.1	22
57	Omalizumab in the Treatment of Urticaria. , 2021, , 167-176.		0
58	Other Interventions for Chronic Urticaria. , 2021, , 177-206.		0
59	History of Urticaria. , 2021, , 1-8.		0
60	Classification and Diagnosis of Urticaria. , 2021, , 25-37.		0
61	The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update. Handbook of Experimental Pharmacology, 2021, 268, 117-133.	1.8	9
62	Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review. Allergologie Select, 2021, 5, 349-360.	3.1	7
63	The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Alergologia, 2021, 4, 155.	0.1	5
64	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
65	Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 423-432.	5.7	213
66	Development of the Angioedema Control Test – A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
67	Is allergy immunotherapy with birch sufficient to treat patients allergic to pollen of tree species of the birch homologous group?. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1327-1336.	5.7	13
68	The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 367-373.	2.3	19
69	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. JDDG - Journal of the German Society of Dermatology, 2020, 18, 737-739.	0.8	6
70	Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. Allergo Journal International, 2020, 29, 129-138.	2.0	5
71	Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clinical and Translational Allergy, 2020, 10, 58.	3.2	56
72	A WAO – ARIA – GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organization Journal, 2020, 13, 100091.	3.5	76

#	ARTICLE	IF	CITATIONS
73	Validation of the Angioedema Control Test (AECT) – A Patient-Reported Outcome Instrument for Assessing Angioedema Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2050-2057.e4.	3.8	50
74	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
75	Answer to the letter to the editor titled –Phenoxyethanol, reproduction, and development: additional studies are needed–. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e409-e410.	2.4	0
76	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA – EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	5.7	114
77	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. <i>World Allergy Organization Journal</i> , 2020, 13, 100080.	3.5	245
78	Dietary implications in acetylsalicylic acid intolerance. <i>Allergo Journal International</i> , 2020, 29, 93-96.	2.0	4
79	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczące definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2020, 7, 1-28.	0.0	2
80	Digital transformation of health and care to sustain Planetary Health: The MASK proof-of-concept for airway diseases – POLLAR symposium under the auspices of Finland – s Presidency of the EU, 2019 and MACVIA-France, Global Alliance against Chronic Respiratory Diseases (GARD, WHO) demonstration project, Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing. <i>Clinical and Translational Allergy</i> , 2020, 10, 24.	3.2	20
81	Urticaria and the gut. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 381-385.	2.3	9
82	Wound Healing Process After Thermomechanical Skin Ablation. <i>Lasers in Surgery and Medicine</i> , 2020, 52, 730-734.	2.1	14
83	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK – air – App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
84	Definition, aims, and implementation of GA – 2 /sup>LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	5.7	29
85	Handling of allergen immunotherapy in the COVID – 19 pandemic: An ARIA – EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	5.7	87
86	In – vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan – An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2161-2169.	5.7	23
87	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 321-333.	2.1	108
88	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. <i>Allergologie Select</i> , 2020, 4, 44-52.	3.1	23
89	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. <i>Allergologie Select</i> , 2020, 4, 53-68.	3.1	38
90	ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem. <i>Allergologie</i> , 2020, 43, 43-72.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Kinetics and tissue repair process following fractional bipolar radiofrequency treatment. <i>Journal of Cosmetic and Laser Therapy</i> , 2019, 21, 71-75.	0.9	5
92	Bronchodilator reversibility in asthma and COPD: findings from three large population studies. <i>European Respiratory Journal</i> , 2019, 54, 1900561.	6.7	74
93	Review of the safety of octocrylene used as an ultraviolet filter in cosmetics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 25-33.	2.4	32
94	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
95	Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 913-921.	0.8	9
96	Safety review of phenoxyethanol when used as a preservative in cosmetics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 15-24.	2.4	59
97	The safety and tolerability profile of bilastine for chronic urticaria in children. <i>Clinical and Translational Allergy</i> , 2019, 9, 55.	3.2	8
98	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	1.4	11
99	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
100	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	1.4	15
101	Atopic Patients Show Increased Interleukin 4 Plasma Levels but the Degree of Elevation Is Not Sufficient to Upregulate Interleukin-4-Sensitive Genes. <i>Skin Pharmacology and Physiology</i> , 2019, 32, 192-200.	2.5	6
102	Diagnosis and treatment of chronic inducible urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2550-2553.	5.7	26
103	Yin-Yang of IL-33 in Human Skin Mast Cells: Reduced Degranulation, but Augmented Histamine Synthesis through p38 Activation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1516-1525.e3.	0.7	39
104	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	3.2	81
105	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
106	IL-33 and MRGPRX2-Triggered Activation of Human Skin Mast Cells Elimination of Receptor Expression on Chronic Exposure, but Reinforced Degranulation on Acute Priming. <i>Cells</i> , 2019, 8, 341.	4.1	42
107	Reply to Wood et al.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 418-419.	5.7	0
108	Untreated allergic rhinitis is a major risk factor contributing to motorcar accidents. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1395-1397.	5.7	4

#	ARTICLE	IF	CITATIONS
109	Time and age trends in smoking cessation in Europe. PLoS ONE, 2019, 14, e0211976.	2.5	46
110	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	3.8	44
111	Real-life treatment of patients with cholinergic urticaria in German-speaking countries. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1141-1147.	0.8	10
112	Testing bronchodilator responsiveness. European Respiratory Journal, 2019, 54, 1902104.	6.7	1
113	Skin type differences in solar-simulated radiation-induced oxidative stress. British Journal of Dermatology, 2019, 180, 597-603.	1.5	44
114	<sc>ARIA</sc> pharmacy 2018 - Allergic rhinitis care pathways for community pharmacy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
115	Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation. Journal of Allergy and Clinical Immunology, 2019, 143, 1246-1248.e4.	2.9	8
116	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	2.9	73
117	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
118	Global Multidisciplinary Networks. , 2019, , 203-205.		0
119	ARIA-Versorgungspfade für die Allergenimmuntherapie 2019. Allergologie, 2019, 42, 404-425.	0.1	2
120	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie Select, 2019, 3, 22-50.	3.1	70
121	Nicht-Zöliakie-Gluten-/Weizen-Sensitivität (NCGS) - ein bislang nicht definiertes Krankheitsbild mit fehlenden Diagnosekriterien und unbekannter Häufigkeit. Allergologie, 2019, 42, 111-117.	0.1	0
122	Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatric Allergy and Immunology, 2018, 29, 630-636.	2.6	57
123	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 477-478.	0.8	51
124	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <sc>MASK</sc> study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1622-1631.	5.7	69
125	Chronic inducible urticaria: A systematic review of treatment options. Journal of Allergy and Clinical Immunology, 2018, 141, 1726-1734.	2.9	66
126	Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholUqoL). Clinical and Experimental Allergy, 2018, 48, 433-444.	2.9	31

#	ARTICLE	IF	CITATIONS
127	Lymphocyte surface markers and cytokines are suitable for detection and potency assessment of skin-sensitizing chemicals in an in vitro model of allergic contact dermatitis: the LCSA-ly. Archives of Toxicology, 2018, 92, 1495-1505.	4.2	15
128	The EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	5.7	1,008
129	Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1763-1774.	5.7	94
130	Executive summary of the methods report for "The EAACI/GA ² LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update" TM . Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1145-1146.	5.7	74
131	Contact sensitization in dental technicians with occupational contact dermatitis. Data of the Information Network of Departments of Dermatology (IVDK) 2001-2015. Contact Dermatitis, 2018, 78, 266-273.	1.4	34
132	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 476-477.	0.8	1
133	Gastritis Can Cause and Trigger Chronic Spontaneous Urticaria Independent of the Presence of <i>Helicobacter pylori</i> . International Archives of Allergy and Immunology, 2018, 175, 246-251.	2.1	15
134	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) -EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
135	Development of tripe palms and soles in a patient with long pre-existing systemic mastocytosis and newly developed non-small cell lung cancer. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e151-e153.	2.4	0
136	Evanescence wave-based technology for the rapid and sensitive quantification of biological analytes. Journal of Allergy and Clinical Immunology, 2018, 141, 817-820.e5.	2.9	1
137	Allergic Fc μ RI and pseudoallergic MRGPRX ² -triggered mast cell activation routes are independent and inversely regulated by SCF. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 256-260.	5.7	68
138	Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e112-e113.	2.4	52
139	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 505-510.	5.7	77
140	Burden of chronic urticaria relative to psoriasis in five European countries. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 282-290.	2.4	35
141	Perspectives in allergen immunotherapy: 2017 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 5-23.	5.7	76
142	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2174-2175.	3.8	0
143	Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer. New England Journal of Medicine, 2018, 379, 2176-2177.	27.0	15
144	Effects of Exposure to New Car Interiors in Patients With Asthma and Allergic Rhinitis. Allergy and Rhinology, 2018, 9, 215265671880006.	1.6	0

#	ARTICLE	IF	CITATIONS
145	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	3.2	104
146	New biologics in the treatment of urticaria. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 425-431.	2.3	27
147	Noninvasive measures in atopic dermatitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 417-424.	2.3	5
148	Non-celiac gluten/wheat sensitivity (NCGS)â€”a currently undefined disorder without validated diagnostic criteria and of unknown prevalence. <i>Allergo Journal International</i> , 2018, 27, 147-151.	2.0	33
149	A Comparison of the United States and International Perspective on Chronic Urticariaâ€™Guidelines. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1144-1151.	3.8	41
150	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 42-44.	1.3	37
151	Reply to Ensina et al. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 670-671.	2.6	1
152	Chronische Urtikaria â€” Was bringt die neue Leitlinie?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 585-595.	0.8	6
153	Economic Burden of the Inadequate Management of Allergic Rhinitis and Urticaria in Asian Countries Based on the GA²LEN Model. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 370.	2.9	44
154	Chronic urticaria â€” What does the new guideline tell us?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 584-593.	0.8	17
155	MI (2-methyl-4-isothiazolin-3-one) contained in detergents is not detectable in machine washed textiles. <i>Clinical and Translational Allergy</i> , 2018, 8, 1.	3.2	32
156	Trends in smoking initiation in Europe over 40 years: A retrospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0201881.	2.5	86
157	<sc>MRGPRX</sc>2 is negatively targeted by <sc>SCF</sc> and <sc>IL</sc>4 to diminish pseudoâ€™allergic stimulation of skin mast cells in culture. <i>Experimental Dermatology</i> , 2018, 27, 1298-1303.	2.9	29
158	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A realâ€™life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2073-2075.	5.7	22
159	Urtikaria. , 2018, , 754-758.		0
160	A novel method to generate monocyte-derived dendritic cells during coculture with HaCaT facilitates detection of weak contact allergens in cosmetics. <i>Archives of Toxicology</i> , 2017, 91, 339-350.	4.2	9
161	Google Trends terms reporting rhinitis and related topics differ in European countries. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1261-1266.	5.7	48
162	Pilot study of mobile phone technology in allergic rhinitis in European countries: the <sc>MASK</sc>â€™rhinitis study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 857-865.	5.7	93

#	ARTICLE	IF	CITATIONS
163	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1035-1042.	5.7	85
164	A novel experimental technology for testing efficacy of air purifiers on pollen reduction. Allergo Journal International, 2017, 26, 1-6.	2.0	14
165	Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 761-773.	2.4	24
166	A novel experimental technology for testing efficacy of air purifiers on pollen reduction. Allergo Journal, 2017, 26, 20-25.	0.1	0
167	Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes. Journal of Allergy and Clinical Immunology, 2017, 139, 388-399.	2.9	145
168	Work productivity in rhinitis using cell phones: The MASK pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	5.7	69
169	An efficient method for gene knockdown by RNA interference in human skin mast cells. Experimental Dermatology, 2017, 26, 1136-1139.	2.9	21
170	Skin allergy. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 262.	2.3	0
171	Responsiveness and minimal important difference of the urticaria control test. Journal of Allergy and Clinical Immunology, 2017, 140, 1710-1713.e11.	2.9	68
172	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
173	Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 278-285.	2.3	9
174	Spatial distribution of allergenic pollen through a large metropolitan area. Environmental Monitoring and Assessment, 2017, 189, 169.	2.7	53
175	German guideline for the management of adverse reactions to ingested histamine. Allergo Journal International, 2017, 26, 72-79.	2.0	69
176	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA – ARIA – EPOS – AIRWAYS ICP statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	5.7	130
177	Birch, grass, and mugwort pollen concentrations and intradiurnal patterns at two different urban sites in Berlin, Germany. Allergo Journal, 2017, 26, 28-36.	0.1	0
178	Birch, grass, and mugwort pollen concentrations and intradiurnal patterns at two different urban sites in Berlin, Germany. Allergo Journal International, 2017, 26, 155-164.	2.0	7
179	Skin mast cell phenotypes between two highly divergent cohorts – more pronounced variability within than between groups. Experimental Dermatology, 2017, 26, 446-449.	2.9	11
180	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	3.3	47

#	ARTICLE	IF	CITATIONS
181	Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. <i>International Journal of Colorectal Disease</i> , 2017, 32, 29-39.	2.2	57
182	Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1158-1166.	2.9	32
183	Technical specifications of the Global Allergy and Asthma European Network (GA2LEN) chamber: a novel mobile allergen exposure chamber. <i>Allergo Journal International</i> , 2017, 26, 287-294.	2.0	10
184	Technical specifications of the Global Allergy and Asthma European Network (GA2LEN) chamber: a novel mobile allergen exposure chamber. <i>Allergo Journal</i> , 2017, 26, 20-27.	0.1	1
185	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRAIL report. <i>Clinical and Translational Allergy</i> , 2017, 7, 37.	3.2	36
186	Retinoic Acid Negatively Impacts Proliferation and MCTC Specific Attributes of Human Skin Derived Mast Cells, but Reinforces Allergic Stimulability. <i>International Journal of Molecular Sciences</i> , 2017, 18, 525.	4.1	30
187	Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study. <i>Clinical and Translational Allergy</i> , 2017, 7, 33.	3.2	15
188	EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. <i>Rhinology</i> , 2017, 55, 202-210.	1.3	36
189	Leitlinie zum Vorgehen bei Verdacht auf Unverträglichkeit gegen¼ber oral aufgenommenem Histamin. <i>Allergologie</i> , 2017, 40, 327-336.	0.1	0
190	Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA ² LEN) survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1603-1611.	5.7	35
191	Histamine intolerance in patients with chronic spontaneous urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1774-1777.	2.4	29
192	Phenotypic variability in human skin mast cells. <i>Experimental Dermatology</i> , 2016, 25, 434-439.	2.9	37
193	Definition, aims, and implementation of ² GA² LEN Urticaria Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1210-1218.	5.7	110
194	Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). <i>Asthma Research and Practice</i> , 2016, 2, 12.	2.4	20
195	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. <i>Clinical and Translational Allergy</i> , 2016, 6, 41.	3.2	24
196	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	3.2	121
197	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
198	Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. <i>Pharmacoeconomics</i> , 2016, 34, 815-827.	3.3	31

#	ARTICLE	IF	CITATIONS
199	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. <i>European Respiratory Journal</i> , 2016, 47, 1028-1033.	6.7	50
200	What is new and upcoming in the world of chronic urticaria?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 5-6.	2.4	0
201	IL-4 and human skin mast cells revisited: reinforcement of a pro-allergic phenotype upon prolonged exposure. <i>Archives of Dermatological Research</i> , 2016, 308, 665-670.	1.9	22
202	Skin provocation tests may help to diagnose atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1745-1752.	5.7	17
203	Controversies and challenges in the management of chronic urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 16-24.	2.4	9
204	Paving the way of systems biology and precision medicine in allergic diseases: the Me ^{DALL} success story. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1513-1525.	5.7	77
205	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 780-802.	5.7	268
206	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	3.2	47
207	Children with Dry Skin and Atopic Predisposition: Outcome Measurement with Validated Scores for Atopic Dermatitis. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 148-156.	2.5	7
208	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. <i>World Allergy Organization Journal</i> , 2016, 9, 33.	3.5	87
209	Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). <i>World Allergy Organization Journal</i> , 2016, 9, 37.	3.5	30
210	A systematic review of the role of interleukin-17 and the interleukin-20 family in inflammatory allergic skin diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 451-457.	2.3	20
211	Pollen season of European beech (<i>Fagus sylvatica</i> L.) and temperature trends at two German monitoring sites over a more than 30-year period. <i>Aerobiologia</i> , 2016, 32, 489-497.	1.7	10
212	Unsaturated compounds induce up-regulation of CD86 on dendritic cells in the in vitro sensitization assay LCSA. <i>Archives of Toxicology</i> , 2016, 90, 927-936.	4.2	4
213	Current and future therapies for treating chronic spontaneous urticaria. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1131-1139.	1.8	10
214	Intradiurnal patterns of allergenic airborne pollen near a city motorway in Berlin, Germany. <i>Aerobiologia</i> , 2016, 32, 199-209.	1.7	13
215	Instrumente zur Erfassung von Krankheitsaktivität, Krankheitskontrolle und Lebensqualitätsbeeinträchtigung bei Patienten mit chronischer Urtikaria und Angioödem. <i>Allergologie</i> , 2016, 39, 6-15.	0.1	6
216	Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel. <i>Allergologie</i> , 2016, 39, 125-136.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Leitlinie zum Management IgE-vermittelter Nahrungsmittelallergien. <i>Allergologie</i> , 2016, 39, 302-344.	0.1	0
218	An individualized diagnostic approach based on guidelines for chronic urticaria (<scp>CU</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 3-11.	2.4	19
219	Diagnostic dilemmas in chronic urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 12-15.	2.4	0
220	Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 38-44.	2.4	32
221	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
222	Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 220-226.	2.3	27
223	The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Przegląd Dermatologiczny</i> , 2015, 2, 155-179.	0.1	11
224	Guideline for the diagnosis of drug hypersensitivity reactions. <i>Allergo Journal International</i> , 2015, 24, 94-105.	2.0	139
225	Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The <scp>M</scp>e<scp>DALL</scp> hypothesis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1062-1078.	5.7	88
226	Guidelines on the management of IgE-mediated food allergies. <i>Allergo Journal International</i> , 2015, 24, 256-293.	2.0	129
227	Omalizumab for the treatment of chronic urticaria. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 171-180.	3.0	20
228	Omalizumab in the treatment of aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 459-460.	3.8	33
229	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2015, 2, T1-T23.	0.0	0
230	Retinoic acid potentiates inflammatory cytokines in human mast cells: Identification of mast cells as prominent constituents of the skin retinoid network. <i>Molecular and Cellular Endocrinology</i> , 2015, 406, 49-59.	3.2	25
231	Allergen and allergy risk assessment, allergen management, and gaps in the European Food Information Regulation (FIR). <i>Allergo Journal International</i> , 2015, 24, 180-184.	2.0	28
232	European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015). <i>Rhinology</i> , 2015, 53, 303-307.	1.3	2
233	Economic burden of inadequate management of allergic diseases in the European Union: a GA²LEN review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1275-1279.	5.7	286
234	Recommendations for the allergy management in the primary care. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 708-718.	5.7	28

#	ARTICLE	IF	CITATIONS
235	Clinical relevance is associated with allergen-specific wheal size in skin prick testing. <i>Clinical and Experimental Allergy</i> , 2014, 44, 407-416.	2.9	68
236	Children with Dry Skin and Atopic Predisposition: Daily Use of Emollients in a Participant-Blinded, Randomized, Prospective Trial. <i>Skin Pharmacology and Physiology</i> , 2014, 27, 208-208.	2.5	18
237	The use of biologicals in cutaneous allergies – present and future. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 409-416.	2.3	11
238	Mast cell transcriptome elucidation: what are the implications for allergic disease in the clinic and where do we go next?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 977-980.	3.0	10
239	The patient's hay-fever diary: three years of results from Germany. <i>Aerobiologia</i> , 2014, 30, 1-11.	1.7	32
240	Food allergies resulting from immunological cross-reactivity with inhalant allergens. <i>Allergo Journal International</i> , 2014, 23, 1-16.	2.0	54
241	Chronic urticaria as a systemic disease. <i>Clinics in Dermatology</i> , 2014, 32, 420-423.	1.6	40
242	The EAACI/GA ² LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 868-887.	5.7	912
243	Urticarial Vasculitis and Schnitzler Syndrome. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 141-147.	1.9	14
244	Commentary on “Dynamic Analysis of Histamine-Mediated Attenuation of Acetylcholine-Induced Sweating via GSK3 ^β Activation”. <i>Journal of Investigative Dermatology</i> , 2014, 134, 302-303.	0.7	0
245	Methods report on the development of the 2013 revision and update of the EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, e1-29.	5.7	75
246	Risk of sensitization and allergy in Ragweed workers – a pilot study. <i>Allergy, Asthma and Clinical Immunology</i> , 2014, 10, 42.	2.0	5
247	Nighttime sedating H ₁ antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014, 171, 148-154.	1.5	58
248	Physical Urticarias and Cholinergic Urticaria. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 73-88.	1.9	95
249	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	6.7	154
250	Redefinition of the human mast cell transcriptome by deep-CAGE sequencing. <i>Blood</i> , 2014, 123, e58-e67.	1.4	175
251	Skin mast cells develop non-synchronized changes in typical lineage characteristics upon culture. <i>Experimental Dermatology</i> , 2014, 23, 933-935.	2.9	32
252	Integration of the Human Dermal Mast Cell into the Organotypic Co-culture Skin Model. <i>Methods in Molecular Biology</i> , 2014, 1192, 69-85.	0.9	2

#	ARTICLE	IF	CITATIONS
253	Nahrungsmittelallergie infolge immunologischer Kreuzreaktivitäten mit Inhalationsallergenen. <i>Allergologie</i> , 2014, 37, 170-189.	0.1	3
254	Management of chronic spontaneous urticaria in real life – in accordance with the guidelines? A cross-sectional physician-based survey study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 43-50.	2.4	59
255	Can On-demand Non-sedating Antihistamines Improve Urticaria Symptoms? A Double-blind, Randomized, Single-dose Study. <i>Acta Dermato-Venereologica</i> , 2013, 93, 168-174.	1.3	42
256	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 751-754.e5.	2.9	52
257	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 971-978.	0.8	39
258	A WAO - ARIA - GA ² LEN consensus document on molecular-based allergy diagnostics. <i>World Allergy Organization Journal</i> , 2013, 6, 17.	3.5	352
259	Two-hours-average values of grass pollen. <i>Allergo Journal</i> , 2013, 22, 480-481.	0.1	0
260	The distribution of pollen and particulate matter in an urban agglomeration using the city of Berlin as an example. <i>Allergo Journal</i> , 2013, 22, 475-479.	0.1	5
261	Pharmacotherapy of chronic spontaneous urticaria. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2511-2519.	1.8	13
262	100 Years of Immunotherapy: The Monaco Charter. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 346-349.	2.1	12
263	Glutathione exposes sequential <sc>I</sc><sc>E</sc>-epitopes in ovomucoid relevant in persistent egg allergy. <i>Molecular Nutrition and Food Research</i> , 2013, 57, 536-544.	3.3	9
264	Personalized pollen-related symptom-forecast information services for allergic rhinitis patients in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 963-965.	5.7	27
265	Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 921-928.	5.7	109
266	Reactive oxygen species and the bacteriostatic and bactericidal effects of isoconazole nitrate. <i>Mycoses</i> , 2013, 56, 16-22.	4.0	10
267	Acupuncture in Patients With Seasonal Allergic Rhinitis. <i>Annals of Internal Medicine</i> , 2013, 158, 225.	3.9	107
268	Randomized controlled trial of desloratadine for persistent allergic rhinitis: Correlations between symptom improvement and quality of life. <i>Allergy and Asthma Proceedings</i> , 2013, 34, 274-282.	2.2	17
269	Classification of urticaria. <i>Indian Journal of Dermatology</i> , 2013, 58, 208.	0.3	10
270	The role of interleukin-1 in allergy-related disorders. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 477-484.	2.3	73

#	ARTICLE	IF	CITATIONS
271	Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. <i>Current Medical Research and Opinion</i> , 2012, 28, 131-139.	1.9	35
272	Is European legislation killing allergy diagnostics?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 475-476.	2.3	11
273	Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective. <i>World Allergy Organization Journal</i> , 2012, 5, 125-147.	3.5	150
274	Testosterone exerts selective anti-inflammatory effects on human skin mast cells in a cell subset dependent manner. <i>Experimental Dermatology</i> , 2012, 21, 878-880.	2.9	19
275	Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 879-886.	0.8	1
276	Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) Seminar. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 943-954.e4.	2.9	68
277	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1049-1062.	2.9	486
278	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA<sup>2</sup><sup>2</sup>LEN – ARIA Position Paper. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 216-231.	2.1	83
279	Chronic Urticaria. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 267-272.	5.3	17
280	Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 9-18.	2.4	33
281	Practical guide to skin prick tests in allergy to aeroallergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 18-24.	5.7	475
282	Cost-intensive, time-consuming, problematical? How physicians in private practice experience the care of urticaria patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 341-347.	0.8	13
283	Kostenintensiv, zeitaufwendig, problematisch? - Die Betreuung von Urtikariapatienten aus der Perspektive niedergelassener Ärzte. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 341-349.	0.8	12
284	Prevention and control of childhood asthma and allergy in the <sc>EU</sc> from the public health point of view: Polish Presidency of the European Union. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 726-731.	5.7	57
285	Efficacy and safety of the interleukin-1 antagonist rilonacept in <sc>S</sc>chnitzler syndrome: an open-label study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 943-950.	5.7	110
286	Effects of a Novel GA2LEN Training Program on Urticaria on the Knowledge of General Practitioners in Saudi-Arabia. <i>World Allergy Organization Journal</i> , 2011, 4, 45-46.	3.5	2
287	Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 202-209.e5.	2.9	303
288	Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). <i>Journal of Dermatological Science</i> , 2011, 62, 36-41.	1.9	28

#	ARTICLE	IF	CITATIONS
289	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
290	Comorbidities between nose and skin allergy. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 457-463.	2.3	18
291	Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 317-330.	5.7	597
292	Viruses and bacteria in acute asthma exacerbations – A GA ² LENâ€DARE* systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 458-468.	5.7	237
293	MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 596-604.	5.7	146
294	Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 840-844.	5.7	72
295	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 765-774.	5.7	67
296	Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1216-1223.	5.7	778
297	Evidence-based (S3) guideline on topical corticosteroids in pregnancy. British Journal of Dermatology, 2011, 165, 943-952.	1.5	75
298	Mast cell-derived TNF- α and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells. Experimental Dermatology, 2011, 20, 1020-1022.	2.9	13
299	Long-Term Cultured Human Skin Mast Cells Are Suitable for Pharmacological Studies of Anti-Allergic Drugs Due to High Responsiveness to Fc ϵ RI Cross-Linking. Bioscience, Biotechnology and Biochemistry, 2011, 75, 382-384.	1.3	29
300	Consensus statement on the management of urticaria. Indian Journal of Dermatology, 2011, 56, 485.	0.3	18
301	Establishing a standardized quality management system for the European Health Network GA ² LEN*. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 743-752.	5.7	7
302	Antihistamines in the Treatment of Urticaria. Advances in Experimental Medicine and Biology, 2010, 709, 67-72.	1.6	3
303	Modern Approaches to the Diagnosis and Treatment of Cold Contact Urticaria. Current Allergy and Asthma Reports, 2010, 10, 243-249.	5.3	37
304	Classification of sensitizing and irritative potential in a combined in-vitro assay. Toxicology and Applied Pharmacology, 2010, 245, 211-218.	2.8	24
305	Erfolgreiche Behandlung des hereditären Angio-Ödems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	7
306	Mast cell lines HMC ϵ 1 and LAD2 in comparison with mature human skin mast cells – drastically reduced levels of tryptase and chymase in mast cell lines. Experimental Dermatology, 2010, 19, 845-847.	2.9	91

#	ARTICLE	IF	CITATIONS
307	Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. <i>British Journal of Dermatology</i> , 2010, 162, 198-200.	1.5	49
308	Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. <i>British Journal of Dermatology</i> , 2010, 162, 674-676.	1.5	59
309	Epidemiology of urticaria: a representative cross-sectional population survey. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 869-873.	1.3	264
310	Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 78-83.	5.7	102
311	Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multicentre, double-blind, randomized, placebo-controlled study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 516-528.	5.7	121
312	Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA ² LEN taskforce position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 290-295.	5.7	92
313	Risk of first-generation H ₁ -antihistamines: a GA ² LEN position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 459-466.	5.7	371
314	Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA ² LEN taskforce position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 959-968.	5.7	62
315	Bilastine in allergic rhinoconjunctivitis and urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1-13.	5.7	33
316	Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1494-1495.	5.7	46
317	Development and implementation of guidelines in allergic rhinitis – an ARIA GA ² LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1212-1221.	5.7	85
318	GA ² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1525-1530.	5.7	185
319	Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA ² LEN Study. <i>International Archives of Allergy and Immunology</i> , 2010, 153, 395-402.	2.1	51
320	The Longest Wheal Diameter Is the Optimal Measurement for the Evaluation of Skin Prick Tests. <i>International Archives of Allergy and Immunology</i> , 2010, 151, 343-345.	2.1	58
321	Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 666-668.e5.	2.9	94
322	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 466-476.	2.9	1,322
323	Treatment strategies in urticaria. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1445-1450.	1.8	11
324	Acute Urticaria. , 2010, , 37-43.		0

#	ARTICLE	IF	CITATIONS
325	Exogenous Histamine Aggravates Eczema in a Subgroup of Patients with Atopic Dermatitis. <i>Acta Dermato-Venereologica</i> , 2009, 89, 52-56.	1.3	22
326	Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. <i>British Journal of Dermatology</i> , 2009, 160, 633-641.	1.5	98
327	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e137-e140.	1.3	21
328	Diagnostic approach for suspected pseudoallergic reaction to food ingredients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 70-77.	0.8	22
329	Diagnostisches Vorgehen bei Verdacht auf eine pseudoallergische Reaktion durch Nahrungsmittelinhaltsstoffe. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 70-77.	0.8	30
330	Chronic urticaria: a patient survey on quality of life, treatment usage and doctor-patient relation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 581-588.	5.7	82
331	The German version of the chronic urticaria quality of life questionnaire: factor analysis, validation, and initial clinical findings. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 927-936.	5.7	145
332	Important research questions in allergy and related diseases: 3-year chronic rhinosinusitis and nasal polyposis - a GA ² LEN study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 520-533.	5.7	102
333	Ragweed sensitization in Europe - GA ² LEN study suggests increasing prevalence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 664-665.	5.7	90
334	GA ² LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma - epidemic. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 969-977.	5.7	95
335	GA ² LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1507-1515.	5.7	248
336	GA ² LEN skin test study I: GA ² LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1498-1506.	5.7	306
337	Efficacy of desloratadine in intermittent allergic rhinitis: a GA ² LEN study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1516-1523.	5.7	55
338	GA ² LEN skin test study III: Minimum battery of test inhalent allergens needed in epidemiological studies in patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1656-1662.	5.7	87
339	EAACI/GA ² LEN/EDF/WAO guideline: management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1427-1443.	5.7	502
340	EAACI/GA ² LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1417-1426.	5.7	582
341	The CONSORT statement checklist in allergen-specific immunotherapy: a GA ² LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1737-1745.	5.7	44
342	Sublingual Immunotherapy: World Allergy Organization Position Paper 2009. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1-59.	5.7	316

#	ARTICLE	IF	CITATIONS
343	High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 672-679.	2.9	187
344	Unmet needs in severe chronic upper airway disease (SCUAD). <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 428-433.	2.9	191
345	ACCEPT : une Étude conjointe de GA2LEN et Schering Plough sur l'implémentation des recommandations ARIA. <i>Revue Francaise D'allergologie</i> , 2009, 49, S69-S73.	0.2	2
346	Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 38-46.	5.7	97
347	A new dendritic cell type suitable as sentinel of contact allergens. <i>Toxicology</i> , 2008, 249, 146-152.	4.2	25
348	Human mast cells in the neurohormonal network: expression of POMC, detection of precursor proteases, and evidence for IgE-dependent secretion of alpha-MSH. <i>Experimental Dermatology</i> , 2008, 15, 643-648.	2.9	0
349	Skin testing with food allergens. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008, 6, 983-988.	0.8	22
350	Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 718-721.	2.4	41
351	Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 247-249.	5.7	112
352	Important questions in allergy: novel research areas. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 143-147.	5.7	15
353	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 8-160.	5.7	3,827
354	Allergic rhinitis management pocket reference 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 990-996.	5.7	134
355	ARIA's suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN Review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 660-669.	5.7	54
356	Primary care: the cornerstone of diagnosis of allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 981-989.	5.7	68
357	Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 842-853.	5.7	158
358	A case-control study of the relation between plasma selenium and asthma in European populations: a GA2LEN project*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 865-871.	5.7	59
359	How to assess disease activity in patients with chronic urticaria?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 777-780.	5.7	327
360	The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA2LEN review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1015-1030.	5.7	35

#	ARTICLE	IF	CITATIONS
361	Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1560-1561.	5.7	14
362	Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1563-1565.	5.7	149
363	The relation between paracetamol use and asthma: a GA2LEN European case-control study. European Respiratory Journal, 2008, 32, 1231-1236.	6.7	69
364	Steroid-Sparing Effect of Pimecrolimus Cream 1% in Children with Severe Atopic Dermatitis. Dermatology, 2007, 215, 325-330.	2.1	36
365	A visit to the mother in law ? a hidden cause for urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 711-712.	5.7	3
366	Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1057-1063.	5.7	119
367	Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1465-1468.	5.7	38
368	A loose-fit coculture of activated keratinocytes and dendritic cell-related cells for prediction of sensitizing potential. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1419-1428.	5.7	33
369	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
370	Urticaria: Current Opinions about Etiology, Diagnosis and Therapy. Acta Dermato-Venereologica, 2007, 87, 196-205.	1.3	109
371	Treatment of atopic dermatitis with pimecrolimus - impact on quality of life. Therapeutics and Clinical Risk Management, 2007, 3, 1021-6.	2.0	5
372	Patient perspectives on the management of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2006, 118, 226-232.	2.9	274
373	EAACI/GA ² LEN/EDF guideline: management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 321-331.	5.7	278
374	EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 316-320.	5.7	221
375	Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 969-987.	5.7	431
376	Allergies and the skin, an interdisciplinary approach in GA2LEN and EAACI activities. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1373-1376.	5.7	10
377	Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells. Experimental Dermatology, 2006, 15, 530-537.	2.9	17
378	Sublinguale Immuntherapie. JDDG - Journal of the German Society of Dermatology, 2006, 4, no.	0.8	0

#	ARTICLE	IF	CITATIONS
379	Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3. <i>Rhinology</i> , 2006, 44, 145-50.	1.3	26
380	Spreading excellence in allergy and asthma: the GA ² LEN (Global Allergy and Asthma) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 858-864.	5.7	47
381	Standard skin prick testing and sensitization to inhalant allergens across Europe â€“ a survey from the GA ² LEN network*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1287-1300.	5.7	210
382	Bivalent Effect of UV Light on Human Skin Mast Cellsâ€™Low-Level Mediator Release at Baseline but Potent Suppression Upon Mast Cell Triggering. <i>Journal of Investigative Dermatology</i> , 2005, 124, 453-456.	0.7	43
383	Evidence for a restricted rather than generalized stimulatory response of skin-derived human mast cells to substance P. <i>Journal of Neuroimmunology</i> , 2005, 163, 92-101.	2.3	58
384	The transcription factor profile of human mast cells in comparison with monocytes and granulocytes. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 214-226.	5.4	32
385	Comparative cytokine profile of human skin mast cells from two compartments-strong resemblance with monocytes at baseline but induction of IL-5 by IL-4 priming. <i>Journal of Leukocyte Biology</i> , 2004, 75, 244-252.	3.3	65
386	Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeability. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 1118-1123.	5.7	78
387	Prevalence of adverse reactions to food in Germany â€“ a population study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 338-345.	5.7	311
388	Urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 1224-1234.	5.7	111
389	Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 343-348.	2.9	85
390	The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 275-280.	2.9	111
391	GM-CSF downmodulates c-kit, FcÎ±RI± and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells. <i>Archives of Dermatological Research</i> , 2001, 293, 249-258.	1.9	40
392	Effect of granulocyte macrophage colony-stimulating factor in a patient with benign systemic mastocytosis.. <i>British Journal of Dermatology</i> , 2001, 145, 661-666.	1.5	6
393	Definition, Classification, and Routine Diagnosis of Urticaria: A Consensus Report11This consensus report is the result of a panel discussion during the International Clinically Oriented ESDR Symposium â€œUrticaria 2000â€œ. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 123-127.	0.8	70
394	Management of Urticaria: A Consensus Report. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 128-131.	0.8	42
395	The Role of Allergens and Pseudoallergens in Urticaria. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 132-134.	0.8	27
396	Mast Cell and Myeloid Marker Expression During Early In Vitro Mast Cell Differentiation from Human Peripheral Blood Mononuclear Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 44-50.	0.7	33

#	ARTICLE	IF	CITATIONS
397	Clinical relevance of food additives in adult patients with atopic dermatitis. <i>Clinical and Experimental Allergy</i> , 2000, 30, 407-414.	2.9	76
398	Anti-Fc ϵ 1 serum autoantibodies in different subtypes of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2000, 55, 951-954.	5.7	65
399	Tannin inhibits histamine release. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 898-899.	5.7	5
400	Alterations in ganglioside expression during the differentiation of human mast cells. <i>Experimental Dermatology</i> , 1999, 8, 380-387.	2.9	12
401	Role of nonallergic hypersensitivity reactions in children with chronic urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 1074-1077.	5.7	68
402	Differential effects of new-generation H ₁ -receptor antagonists in pruritic dermatoses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 180-183.	5.7	38
403	Most chronic urticaria is food-dependent, and not idiopathic. <i>Experimental Dermatology</i> , 1998, 7, 139-142.	2.9	26
404	Gastrointestinal barrier in patients with chronic recurrent urticaria: Effect of a low-pseudoallergen diet. <i>Gastroenterology</i> , 1998, 114, A868.	1.3	1
405	GM-CSF Downregulates Expression of Tryptase, Fc Epsilon R1 and Histamine in HMC-1 Mast Cells. <i>International Archives of Allergy and Immunology</i> , 1997, 113, 284-286.	2.1	14
406	Enhanced P-Selectin Expression in Chronic and Dermographic Urticaria. <i>International Archives of Allergy and Immunology</i> , 1997, 114, 86-89.	2.1	50
407	740 Characterization of naturally occurring pseudoallergens causing chronic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 367-367.	2.9	22
408	High response rate to additive-free diet in chronic urticaria. <i>British Journal of Dermatology</i> , 1996, 134, 1159-1159.	1.5	4
409	Histamine releasability of basophils and skin mast cells in chronic urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1996, 51, 24-28.	5.7	27
410	Double-Blind Crossover Study of High-Dose Cetirizine in Cholinergic Urticaria. <i>Dermatology</i> , 1996, 193, 324-327.	2.1	106
411	Acute urticaria: clinical aspects and therapeutic responsiveness.. <i>Acta Dermato-Venereologica</i> , 1996, 76, 295-297.	1.3	116
412	MAST CELLS. <i>International Journal of Dermatology</i> , 1995, 34, 1-10.	1.0	71
413	Efficacy of cetirizine in cholinergic urticaria.. <i>Acta Dermato-Venereologica</i> , 1995, 75, 147-149.	1.3	24
414	Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study.. <i>Acta Dermato-Venereologica</i> , 1995, 75, 484-487.	1.3	115

#	ARTICLE	IF	CITATIONS
415	Prevalence of cholinergic urticaria in young adults. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, 978-981.	1.2	96
416	β^2 -arrestin-1 and β^2 -arrestin-2 Restrain MRGPRX2-Triggered Degranulation and ERK1/2 Activation in Human Skin Mast Cells. <i>Frontiers in Allergy</i> , 0, 3, .	2.8	11